Supernus Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Supernus Pharma (SUPN) Tops Q3 EPS by 44c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
November 3, 2020 4:33 PM ESTSupernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.74, $0.44 better than the analyst estimate of $0.30. Revenue for the quarter came in at $155.1 million versus the consensus estimate of $130.66 million.
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020... More